17:49 , May 11, 2018 |  BC Week In Review  |  Clinical News

Arcus reports Phase I safety data for cancer candidate AB928

Arcus Biosciences Inc. (NYSE:RCUS) reported data from 85 healthy volunteers in a Phase I trial showing that single and multiple ascending doses of cancer candidate AB928 were well tolerated. Data were presented at the American...
18:00 , Mar 16, 2018 |  BC Week In Review  |  Financial News

Arcus raises upsized $120M IPO

Arcus Biosciences Inc. (NYSE:RCUS) raised on March 14 $120 million through the sale of 8 million shares at $15 in an upsized IPO underwritten by Citigroup, Goldman Sachs and Leerink. The IPO price valued Arcus...
17:49 , Mar 15, 2018 |  BC Extra  |  Financial News

Modest first-day pop for Arcus after upsized $120M IPO

Arcus Biosciences Inc. (NYSE:RCUS) climbed $2.08 (14%) to $17.08 on Thursday after raising $120 million through the sale of 8 million shares at $15 in an upsized IPO underwritten by Citigroup, Goldman Sachs and Leerink....
20:28 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Immuno-oncology play Arcus raises $107M

On Nov. 13, immuno-oncology company Arcus Biosciences (Hayward, Calif.) raised $107 million in a untranched series C round led by existing investor GV. New investors Wellington Management, EcoR1 Capital, BVF Partners, Decheng Capital, Hillhouse, Aisling Capital...
00:01 , Nov 14, 2017 |  BC Extra  |  Financial News

Immuno-oncology play Arcus raises $107M

Immuno-oncology company Arcus Biosciences (Hayward, Calif.) raised $107 million in a untranched series C round led by existing investor GV. New investors Wellington Management, EcoR1 Capital, BVF Partners, Decheng Capital, Hillhouse, Aisling Capital and Leerink Partners...